TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03964636

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A (optical coherence tomography)
Description: Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A (optical coherence tomography)
Description: Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A (optical coherence tomography)
Description: Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
Study: NCT02166320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially covered SEMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully covered SEMS
Study: NCT03103074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum B Toxin
Description: Intradermal injections
Study: NCT04646980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biobran/MGN-3
Description: Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
Study: NCT00665496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10 mg and 20 mg orally once a day as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT03747458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study: NCT03103074

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: Intradermal injections
Study: NCT00523328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9924
Description: dosage administered as per Biogen-idec protocol
Study: NCT01564199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol / fluticasone propionate
Description: 100/1000 μg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol / fluticasone propionate
Description: 100/1000 μg oral capsule
Study: NCT04208802

Intervention type: OTHER
Intervention: Use of fluoridated toothpaste
Description: Use of fluoridated toothpaste

Intervention type: OTHER
Intervention: Use of fluoridated toothpaste
Description: Use of fluoridated toothpaste

Intervention type: OTHER
Intervention: Wearing of an intraoral device with bovine tooth samples
Description: Wearing of an intraoral device with bovine tooth samples

Intervention type: OTHER
Intervention: Wearing of an intraoral device with bovine tooth samples
Description: Wearing of an intraoral device with bovine tooth samples

Intervention type: OTHER
Intervention: Wearing of an intraoral device with resin samples
Description: Wearing of an intraoral device with resin samples

Intervention type: OTHER
Intervention: Wearing of an intraoral device with resin samples
Description: Wearing of an intraoral device with resin samples
Study: NCT02066441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-D-Mulsion Forte®
Description: According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03874650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Planning Group
Description: Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Engagement Group
Description: Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Group
Description: Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
Study: NCT00414648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo dose of 2 tablets per day for 1 year.
Study: NCT02045719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uncaria tomentosa (cat´s claw)
Study: NCT01569919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax®
Description: Dose of 1 x 10\^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000μg intramuscular, Day 2 of weeks 3 and 12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 400μg oral daily from Day 2 of week 3 to Day 2 of week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4mg BD, Days 2-6 of weeks 4, 7, 10, 13
Study: NCT05380869

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point-of-care Test
Description: to test Point-of-care procalcitonin in suspected pneumonia
Study: NCT01826695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic technique group
Description: Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
Study: NCT01957319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Study: NCT03608618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCY-M11
Description: Intraperitoneal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCY-M11
Description: Intraperitoneal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCY-M11
Description: Intraperitoneal administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCY-M11
Description: Intraperitoneal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous administration for preconditioning
Study: NCT03134950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
Study: NCT00668655

Intervention type: DRUG
Intervention: Metronidazole Gel
Description: Topical, Once daily for 2 weeks
Study: NCT02811536

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: optical coherence tomography angiography
Description: Imaging with optical coherence tomography angiography
Study: NCT01044381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Solution, 10%
Description: 28 days of daily application
Study: NCT00074412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nevirapine placebo
Description: Oral suspension taken once daily up to 6 months of age
Study: NCT04310215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARTISTEM®
Description: \*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture~2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: \*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture
Study: NCT00382980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Vero cell based whole virus influenza A/H5N1
Description: Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Vero cell based whole virus influenza A/H5N1
Description: Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Vero cell based whole virus influenza A/H5N1
Description: Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Vero cell based whole virus influenza A/H5N1
Description: Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Vero cell based whole virus influenza A/H5N1
Description: Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
Study: NCT03505138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group intervention
Description: GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health care system
Description: GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year.
Study: NCT04821973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radius PPG Tetherless Pulse Oximetry (Masimo)
Description: continuous monitoring by a portable, wireless and stand-alone device
Study: NCT03608618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous administration for preconditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous administration for preconditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous administration for preconditioning
Study: NCT01002768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
Study: NCT03907046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin is an oral antiplatelet drug.
Study: NCT04542031

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire to be completed at 6 and 12 months
Study: NCT01385189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Na-GST-1/Alhydrogel
Description: 3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel
Description: 3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 μg Na-GST-1/Alhydrogel
Description: 3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
Description: 3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
Description: 3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
Description: 3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
Description: 3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
Study: NCT02842684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TraumaCad software
Description: restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
Study: NCT01615263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung isolation device
Description: Lung isolation for one-lung ventilation with a left double lumen tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung isolation device
Description: Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
Study: NCT04591652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIRC208
Description: 99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
Study: NCT03176355

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Canaliculo- Dacryocystorhinostomy
Description: Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
Study: NCT00594113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch 2 Screen
Description: Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch screen intervention
Description: Touch screen intervention
Study: NCT03320096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization
Description: Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3\*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
Study: NCT03710590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 15 watts, 10 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 15 watts, 10 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 15 watts, 15 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 15 watts, 15 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 15 watts, 30 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 15 watts, 30 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 30 watts, 10 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 30 watts, 10 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 30 watts, 15 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 30 watts, 15 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 30 watts, 30 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session 30 watts, 30 mg nicotine
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
Study: NCT01865929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic hysterectomy
Description: Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal or laparoscopic hysterectomy
Description: Benign hysterectomy performed by traditional minimal invasive procedures.
Study: NCT04821973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: usual monitoring
Description: usual nurse respiratory monitoring
Study: NCT02847208

Intervention type: OTHER
Intervention: self-report written questionnaire
Description: The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.